Biosergen AB Logo

Biosergen AB

Developing novel antifungal drugs for life-threatening infections in immunocompromised patients.

BIOSGN | ST

Overview

Corporate Details

ISIN(s):
SE0016013460 (+2 more)
LEI:
549300YD2OGUE7BMP925
Country:
Sweden
Address:
Fogdevreten 2, 171 65 Solna
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Biosergen AB is a clinical-stage biotechnology company dedicated to developing innovative treatments for life-threatening invasive fungal infections. The company's lead candidate, BSG005, is a genetically improved, fungicidal polyene macrolide designed to offer a superior safety and potency profile compared to current antifungal therapies. BSG005 targets a wide spectrum of fungal pathogens and is primarily being developed for immunocompromised patients, such as those undergoing cancer treatment or organ transplantation. Originating from research at the Norwegian University of Science and Technology, the drug has received FDA Orphan Drug Designation. Through clinical trials and strategic collaborations, Biosergen aims to address the significant unmet medical need in treating severe and resistant fungal diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Biosergen AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Biosergen AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Global provider of medical aesthetic solutions like botulinum toxin and HA fillers.
South Korea 145020
Human Stem Cells Institute PJSC Logo
A biotech investor developing gene therapy, regenerative medicine, and genetic services.
Russian Federation ISKJ
HUMASIS CO., LTD. Logo
Develops & manufactures rapid in-vitro diagnostic test kits & instruments for global POCT markets.
South Korea 205470
Humedix Co., Ltd. Logo
Develops hyaluronic acid-based pharma, aesthetics, medical devices, and offers CMO services.
South Korea 200670
HUONS CO., LTD. Logo
Global healthcare company providing pharmaceuticals, medical devices, and wellness products.
South Korea 243070
Huons Global Co., Ltd. Logo
Develops pharmaceuticals, medical devices, cosmetics, and health foods for the global market.
South Korea 084110
Hong Kong N/A
HWAIL PHARM. CO., LTD Logo
Develops and manufactures APIs, finished drugs, and functional ingredients for healthcare.
South Korea 061250
Hyloris Pharmaceuticals SA Logo
A biopharma company optimizing existing drugs for unmet needs via abbreviated pathways.
Belgium HYL
HYUNDAI BIOLAND Co.,Ltd. Logo
Develops natural biomaterials for cosmetics, nutraceuticals, and regenerative medicine globally.
South Korea 052260

Talk to a Data Expert

Have a question? We'll get back to you promptly.